The Centre has halted the production of drugs in 31 companies and revoked or suspended product licenses for 50 firms due to their failure to comply with quality control regulations. Moreover, 73 firms have received show-cause notices, and warning letters have been issued to 21 companies.

These actions result from a nationwide inspection conducted by drug regulatory bodies, targeting drug manufacturing units identified as being at risk of producing Not of Standard Quality (NSQ), adulterated, or spurious drugs. The inspections were prompted by recent controversies surrounding alleged adulteration in certain products, primarily cold and cough syrups exported abroad.

On Tuesday, Union Minister of chemicals and fertilisers, Mansukh Mandaviya held a meeting with representatives of several pharmaceutical companies on the matter and said, “It is important for MSME pharma cos. to be alert to quality of drugs and expeditiously move towards good manufacturing processes through self-regulation.”

He also directed the DCGI to take stringent action against all companies that make spurious drugs. “There shall be no compromise with the quality of drugs manufactured in India”, he stated.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!